Protocol Ledger

NCT04434092 · Phase III · ACTIVE NOT RECRUITING

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Interventional Phase III clinical trial protocol NCT04434092 sponsored by Roche / Genentech in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-08 Enrollment: 210 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04434092
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)210 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04434092
Protocol FieldVerified Registry Value
NCT IdentifierNCT04434092
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment210 participants (ACTUAL)
Registered Start Date2020-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI